Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Share-based Compensation (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Share-based Compensation data on record, last reported at $11.3 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 8.48% year-over-year to $11.3 million; the TTM value through Dec 2025 reached $47.5 million, up 10.41%, while the annual FY2025 figure was $47.5 million, 10.41% up from the prior year.
  • Share-based Compensation reached $11.3 million in Q4 2025 per SNDX's latest filing, down from $12.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.8 million in Q2 2025 and bottomed at $2.8 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $7.5 million, with a median of $8.2 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 104.8% in 2023, then decreased 8.48% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.9 million in 2021, then increased by 7.94% to $4.2 million in 2022, then skyrocketed by 96.35% to $8.3 million in 2023, then skyrocketed by 47.68% to $12.3 million in 2024, then dropped by 8.48% to $11.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $11.3 million in Q4 2025, $12.1 million in Q3 2025, and $13.8 million in Q2 2025.